Wednesday, March 2, 2022 Daily Archives

Improve Your Cell Line Development Workflows with Analytical Tools

by

This webcast features: Dirk Müller, PhD, Manager of Media & Process Development, Sartorius, Lukas Klein, Scientist, Sartorius. Cell line development involves screening thousands of clones to find those that are stable, produce high yields of the bioproduct, and exhibit desired critical quality attributes (CQAs). While there are multiple CQAs that need to be monitored early in the development process, product yield, cell count and viability assessment remain the main attributes by which process conditions are optimized. Incorporating analytical techniques into…

March 2, 2022

ConserV receives UK Aid funding for pan-coronavirus candidate

by

ConserV Bioscience has been awarded £415,000 ($556,000) by UK Aid funding to drive development of a coronavirus vaccine immune to variants, UNICOR-v. The firm claims UNICOR-v could possibly protect people against future epidemics caused by a coronavirus spreading from animals to human, as well as new variants that could emerge from SARS-Cov-2 without needing a frequent booster. UNICOR-v consists of twelve antigens from conserved regions, which includes clusters of reactive T-cell epitopes for various human leukocyte antigens (HLAs). It aims…

March 2, 2022

FDA approves J&J’s myeloma cell therapy

by

The US FDA has approved a CAR-T therapy developed by Johnson & Johnson and its partner Legend Biotech to treat white blood cell cancer. J&J division Janssen Biotech entered the cell and gene therapy space in 2017, teaming up with Legend Biotech for the development of Carvykti ( ciltacabtagene autoleucel; ciltacel), a chimeric antigen receptor T-cell (CAR-T) therapy that specifically targets the B-cell maturation antigen (BCMA) and is known as LCAR-B38M in China. Now, the US Food and Drug Administration (FDA) has…

March 2, 2022